This filing contains no material financial or operational data. Monitor for upcoming Phase 2b/3 trial initiation of urcosimod in NCP (targeted for H1 2026) as a more significant catalyst. The SAB addition is incremental but not market-moving.
Price Chart
Executive Summary
OKYO Pharma announced the appointment of Dr. Marta Sacchetti to its Scientific Advisory Board. Dr. Sacchetti's expertise in ocular inflammatory and degenerative diseases is expected to support the clinical development of urcosimod (formerly OK-101) for neuropathic corneal pain (NCP). The filing also notes OKYO's engagement at the ASCRS, Eyecelerator, and ARVO conferences. This is a routine clinical-stage biopharma SAB addition with no financial terms or material operational changes disclosed.
Key Facts
- Appointed Marta Sacchetti, MD, PhD to Scientific Advisory Board, effective May 19, 2026.
- Dr. Sacchetti brings expertise in corneal and ocular surface diseases; previously Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici.
- OKYO's lead asset urcosimod has Fast Track designation from FDA for NCP; positive Phase 2 data announced but no new trial results or regulatory milestones in this filing.
- No financial terms, equity grants, or changes to pipeline/guidance disclosed.
Financial Impact
No financial information provided; routine SAB appointment.
Risk Factors
- No immediate catalysts; stock may trade on pipeline milestones rather than this appointment.
- Clinical-stage biotech carries inherent development and regulatory risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-024343 |
| Exhibit: ex99-1.htm | 0001493152-26-024343 |
| Document: 0001493152-26-024343-index-headers.html | 0001493152-26-024343 |
| Document: 0001493152-26-024343-index.html | 0001493152-26-024343 |
| Document: 0001493152-26-024343.txt | 0001493152-26-024343 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers